AUSTIN, Texas--(BUSINESS WIRE)--Astrogenetix, Inc., a subsidiary of the Astrotech Corporation (Nasdaq:SPAB), today announced it is conducting novel pharmaceutical research aboard Shuttle Discovery (STS-119) on NASA mission 15A scheduled to launch this evening and destined for the International Space Station (ISS). Astrogenetix is conducting a microgravity-based virulence survey study with methicillin-resistant Staphylococcus aureus (MRSA), Listeria monocytogenes, Enterococcus faecalis and Candida albicans The research will utilize the unique environment of microgravity, which is known to impact virulence (infection potential) of microbes, to help discover potential targets for a vaccine or therapeutic agent to fight infections caused by these microbes.
